Published in Transplant Rev (Orlando) on July 23, 2010
Targeting B cells and antibody in transplantation. Am J Transplant (2011) 1.34
Essential role for B cells in transplantation tolerance. Curr Opin Immunol (2011) 0.89
Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment. Immunol Lett (2012) 0.86
Rational clinical trial design for antibody mediated renal allograft injury. Front Biosci (Landmark Ed) (2015) 0.75
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
Predominant autoantibody production by early human B cell precursors. Science (2003) 13.14
Regulation of the germinal center response by microRNA-155. Science (2007) 12.25
MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell (2007) 9.33
Maintenance of serological memory by polyclonal activation of human memory B cells. Science (2002) 8.75
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42
Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med (1999) 7.41
MicroRNA control in the immune system: basic principles. Cell (2009) 7.16
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 5.99
Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med (1993) 5.49
Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature (1989) 5.48
Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med (1955) 4.89
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity (2004) 4.42
BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med (2004) 4.41
Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature (1994) 4.36
Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med (2003) 4.35
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A (2007) 4.15
Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature (1991) 4.04
Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity (2004) 4.00
Regulation of plasma-cell development. Nat Rev Immunol (2005) 3.98
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity (2001) 3.43
BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med (2000) 3.43
Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature (1991) 3.32
Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet (2009) 3.09
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (2005) 3.00
Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature (1995) 2.95
Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature (2005) 2.89
Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. J Immunol (1993) 2.86
Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest (2007) 2.81
Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol (2001) 2.75
Evidence for the clonal abortion theory of B-lymphocyte tolerance. J Exp Med (1975) 2.61
B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med (2009) 2.56
Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice. Nature (1992) 2.52
Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol (2008) 2.38
MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A (2009) 2.36
Peripheral deletion of self-reactive B cells. Nature (1991) 2.34
Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity (2006) 2.33
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum (2006) 2.17
The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol Rev (1997) 2.16
Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol (2002) 2.16
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther (2008) 2.15
Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med (1994) 2.15
B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature (1993) 2.14
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest (2005) 2.10
BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum (2007) 2.08
B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med (2000) 2.02
Antibody-mediated organ-allograft rejection. Nat Rev Immunol (2005) 1.99
B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol (2008) 1.99
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood (2005) 1.96
Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol (2008) 1.96
B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A (2009) 1.95
Circulating T and B lymphocytes of the mouse. II. Lifespan. Cell Immunol (1973) 1.94
Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med (2004) 1.92
BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A (2008) 1.88
TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood (2007) 1.85
Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation (2008) 1.84
An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov (2006) 1.84
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum (2007) 1.79
A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant (2008) 1.79
Peripheral B cell maturation. I. Immature peripheral B cells in adults are heat-stable antigenhi and exhibit unique signaling characteristics. J Immunol (1992) 1.77
B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes (1997) 1.75
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation (2008) 1.66
B-cell self-tolerance in humans. Adv Immunol (2007) 1.65
Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood (2007) 1.64
Regulation of anti-double-stranded DNA B cells in nonautoimmune mice: localization to the T-B interface of the splenic follicle. J Exp Med (1997) 1.63
Deletion and editing of B cells that express antibodies to DNA. J Immunol (1994) 1.62
Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol (2006) 1.60
Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant (2007) 1.60
Space, selection, and surveillance: setting boundaries with BLyS. J Immunol (2006) 1.55
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2010) 1.55
Engagement of the antigen-receptor on immature murine B lymphocytes results in death by apoptosis. J Immunol (1995) 1.54
B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med (2007) 1.53
"To B or not to B?" B-cells and graft rejection. Transplantation (2008) 1.51
Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells. J Exp Med (1996) 1.50
Transitional B cells: step by step towards immune competence. Trends Immunol (2003) 1.50
Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis (2006) 1.47
Migration of bone marrow lymphocytes demonstrated by selective bone marrow labeling with thymidine-H3. Anat Rec (1970) 1.46
Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation (2008) 1.44
Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors. J Immunol (2003) 1.42
Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol (2009) 1.41
Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation (2007) 1.41
Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse. J Immunol (1996) 1.40
Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem (2004) 1.38
NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. J Immunol (2003) 1.38
Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum (2008) 1.38
Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant (2008) 1.37
T cells within germinal centers are specific for the immunizing antigen. J Immunol (1993) 1.34
B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol (2006) 1.34
Regulation of B cell self-tolerance by BAFF. Semin Immunol (2006) 1.34
Germinal center reutilization by newly activated B cells. J Exp Med (2009) 1.34
Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation (2004) 1.31
ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation (2008) 1.31
Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant (2003) 1.29
B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am J Transplant (2009) 1.27
Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation (2009) 1.26
Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant (2009) 1.26
Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation (2001) 1.24
Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care (2012) 3.20
Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol (2009) 2.48
Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling. Science (2003) 2.46
Epigenomic plasticity enables human pancreatic α to β cell reprogramming. J Clin Invest (2013) 2.38
Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat Med (2002) 2.29
Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes (2004) 2.22
Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum (2012) 2.21
Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum (2003) 2.21
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum (2006) 2.17
Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol (2002) 2.16
Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol (2008) 1.96
Elevated mouse hepatic betatrophin expression does not increase human β-cell replication in the transplant setting. Diabetes (2013) 1.90
BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A (2008) 1.88
A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood (2011) 1.84
Cutting edge: dendritic cell-restricted antigen presentation initiates the follicular helper T cell program but cannot complete ultimate effector differentiation. J Immunol (2011) 1.84
BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol (2002) 1.77
Impact of persistent HIV replication on CD4 negative Vγ2Vδ2 T cells. J Infect Dis (2012) 1.70
Insulin independence following isolated islet transplantation and single islet infusions. Ann Surg (2003) 1.67
TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model. Nat Biotechnol (2003) 1.63
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum (2012) 1.59
TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol (2007) 1.56
Space, selection, and surveillance: setting boundaries with BLyS. J Immunol (2006) 1.55
B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med (2007) 1.53
Improved renal ischemia tolerance in females influences kidney transplantation outcomes. J Clin Invest (2016) 1.51
Genome-wide analysis of histone modifications in human pancreatic islets. Genome Res (2010) 1.51
A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 1.44
Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors. J Immunol (2003) 1.42
When Do DCD Donors Die?: Outcomes and Implications of DCD at a High-volume, Single-center OPO in the United States. Ann Surg (2016) 1.42
Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis (2008) 1.42
Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice. J Exp Med (2010) 1.41
Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A (2009) 1.41
Avoiding tracheostomy: submental intubation in faciomaxillary trauma surgery. Plast Reconstr Surg (2004) 1.39
HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS (2007) 1.38
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther (2006) 1.36
Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr (2009) 1.34
Bone marrow microenvironmental changes underlie reduced RAG-mediated recombination and B cell generation in aged mice. J Exp Med (2004) 1.34
B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol (2006) 1.34
Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Transplantation (2003) 1.32
{beta}-Cell function following human islet transplantation for type 1 diabetes. Diabetes (2005) 1.28
Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes (2003) 1.27
B cell maintenance and function in aging. Semin Immunol (2012) 1.25
Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes (2003) 1.25
The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys (2008) 1.23
CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1. AIDS (2007) 1.23
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis (2008) 1.22
BAFF and the plasticity of peripheral B cell tolerance. Curr Opin Immunol (2008) 1.20
Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res (2003) 1.18
The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. Int Immunol (2007) 1.18
Research resource: the pdx1 cistrome of pancreatic islets. Mol Endocrinol (2012) 1.17
Islet cell hormonal responses to hypoglycemia after human islet transplantation for type 1 diabetes. Diabetes (2005) 1.16
Improvement in β-cell secretory capacity after human islet transplantation according to the CIT07 protocol. Diabetes (2013) 1.15
Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med (2011) 1.15
Transplantation for type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Ann Surg (2004) 1.15
RS rearrangement frequency as a marker of receptor editing in lupus and type 1 diabetes. J Exp Med (2008) 1.14
In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J Immunol (2008) 1.14
Hepatitis C infection in HIV-1 natural viral suppressors. AIDS (2010) 1.13
Overexpression of hepatocyte nuclear factor-4α initiates cell cycle entry, but is not sufficient to promote β-cell expansion in human islets. Mol Endocrinol (2012) 1.13
Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire. J Infect Dis (2004) 1.10
Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol (2012) 1.10
Asymmetric B cell division in the germinal center reaction. Science (2011) 1.10
Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci U S A (2008) 1.09
Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem (2010) 1.09
MicroRNA-7 regulates the mTOR pathway and proliferation in adult pancreatic β-cells. Diabetes (2012) 1.08
Insulin sensitivity, glucose effectiveness, and free fatty acid dynamics after human islet transplantation for type 1 diabetes. J Clin Endocrinol Metab (2006) 1.07
Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med (2013) 1.06
BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells. Semin Immunol (2006) 1.06
Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells. AIDS (2009) 1.05
{beta}-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. J Clin Endocrinol Metab (2010) 1.04
Glycemic thresholds for activation of counterregulatory hormone and symptom responses in islet transplant recipients. J Clin Endocrinol Metab (2006) 1.04
The use of non-heart-beating donors for isolated pancreatic islet transplantation. Transplantation (2003) 1.03
Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics. Am J Physiol Endocrinol Metab (2011) 1.03
Targeting the cell cycle inhibitor p57Kip2 promotes adult human β cell replication. J Clin Invest (2014) 1.02
Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors. AIDS (2012) 1.02
Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits. Toxins (Basel) (2013) 1.01
Alloreactive CD4 T cell activation in vivo: an autonomous function of the indirect pathway of alloantigen presentation. J Immunol (2003) 1.01
Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI. J Clin Invest (2011) 1.01
Regulation of glucagon secretion in normal and diabetic human islets by γ-hydroxybutyrate and glycine. J Biol Chem (2012) 1.00
Comparison of open, laparoscopic, and hand-assisted approaches to live-donor nephrectomy. Transplantation (2002) 0.99
High cancer-related mortality in an urban, predominantly African-American, HIV-infected population. AIDS (2013) 0.99
Acute insulin responses to glucose and arginine as predictors of beta-cell secretory capacity in human islet transplantation. Transplantation (2007) 0.99
Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol (2011) 0.99
Homeostatic niche specification among naïve and activated B cells: a growing role for the BLyS family of receptors and ligands. Semin Immunol (2005) 0.99
Mechanism and regulatory function of CpG signaling via scavenger receptor B1 in primary B cells. J Biol Chem (2009) 0.98
Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics. J Acquir Immune Defic Syndr (2012) 0.98
HLA sensitization in islet transplantation. Clin Transpl (2006) 0.97
Long-lived bone marrow plasma cells are induced early in response to T cell-independent or T cell-dependent antigens. J Immunol (2012) 0.97
Cutting edge: impaired transitional B cell production and selection in the nonobese diabetic mouse. J Immunol (2006) 0.97
Travelling with the BAFF/BLyS family: are we there yet? Semin Immunol (2006) 0.97